What's Fueling The Recent Diagnostics Dealmaking?
By
Mark Ratner / Email the Author / IN VIVO April 2011, Vol. 29, No. 4
Feature Articles / Word Count: 2879 / Article # 2011800059
Executive Summary
A variety of new players have become active dealmakers around personalized medicine diagnostics tests and services. One way to put these deals in context is to view the acquired assets through the lens of how they are to be deployed. To a large extent, the transactions are being driven by the interests of drugmakers, which are seeking new tools to assist them in clinical trials, thus creating more opportunity for the acquirers to offer clinical development services.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.